restrictive fluid administration

PreclinicalSmall molecule

restrictive fluid administration is one of 4 small molecule programs targeting Thoracic Surgery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thoracic SurgeryUnknown status

Thoracic SurgeryPreclinical

Unknown status

Competition

Competitive Landscape

5 competitors in Thoracic Surgery

#DrugCompanyPhaseTrials

Dexmedetomidine Hydrochloride

Pfizer

Preclinical

1 2

S-Ketamine

PPeking University First Hospital

Preclinical

1 3

Vasoconstrictor Agents

UUniversity Hospitals Cleveland Medical Center

Preclinical

1 4

restrictive fluid administration

TTel-Aviv Sourasky Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thoracic Surgery1 trial

Effect of Intraoperative Fluid Restriction on Postoperative Outcomes in Video-assisted Thoracic Surgery (VATS)

Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT00854386·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for restrictive fluid administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — restrictive fluid administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for restrictive fluid administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tel-Aviv Sourasky Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTel-Aviv Sourasky Medical Center

restrictive fluid administration

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thoracic Surgery1 trial

References

Drug Info

Quick Facts

Related News